et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107702 (Peer Reviewed)
RCT with 55 patients (36 favipiravir, 19 control) who were PCR+ after recovery, showing improved viral clearance with treatment.
Zhao et al., 4/21/2021, Randomized Controlled Trial, China, Asia, peer-reviewed, 25 authors.
risk of no virological cure, 59.0% lower, RR 0.41, p = 0.06, treatment 7 of 36 (19.4%), control 9 of 19 (47.4%).
time to viral-, 52.4% lower, relative time 0.48, p = 0.04, treatment 36, control 19.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.